Back to Search Start Over

The therapeutic effect and mechanisms of ABP501, an adalimumab biosimilar, in rheumatoid arthritis

Authors :
Liu Ziming
Source :
E3S Web of Conferences, Vol 553, p 05024 (2024)
Publication Year :
2024
Publisher :
EDP Sciences, 2024.

Abstract

Adalimumab is one of the most widely used antibodies in the world. With the expiration of its patent rights, a large number of drugs with similar biological functions began to emerge. There are already three ADalimumab generic drugs in Europe and/or the United States: ABP501 (AMJEVITA/Solymbic) produced by Amgen, BI695501 (Cyltezo) produced by Boehringer-Ingelheim, and SB5 (Imraldi) produced by Samsung. All three agents meet the predetermined reciprocity criteria. Adalimumab inhibits the biological activity of TNF- α by inhibiting the binding of TNF- α to P55 and p75. The researchers point out that there are small differences in side effects and clinical reactions between reference drugs and similar drugs. In this study, the biological experimental results of RA were analyzed and evaluated. The launch of biological generics of adalizumab will provide us with an exciting opportunity to provide more choices for our patients in RA and other approved drugs. In order to better ensure its correctness and security, it is also necessary to use actual data.

Subjects

Subjects :
Environmental sciences
GE1-350

Details

Language :
English, French
ISSN :
22671242
Volume :
553
Database :
Directory of Open Access Journals
Journal :
E3S Web of Conferences
Publication Type :
Academic Journal
Accession number :
edsdoj.5921b86b1374d85ae6695eec234237a
Document Type :
article
Full Text :
https://doi.org/10.1051/e3sconf/202455305024